Core Viewpoint - The AI Fund Manulife Dividend Pioneer Mixed A (162212) reported a profit of 942,000 yuan for Q2 2025, with a weighted average profit per fund share of 0.0171 yuan, and a net value growth rate of 1.98% during the reporting period [3][17]. Fund Performance - As of July 18, the fund's unit net value was 0.989 yuan, with a one-year cumulative growth rate of 8.09%, ranking 127 out of 133 comparable funds [3][4]. - The fund's three-month cumulative growth rate was 12.64%, ranking 119 out of 138 comparable funds, and the six-month growth rate was 10.13%, ranking 132 out of 138 [4]. Investment Strategy - The fund focuses on long-term investments in pharmaceutical and medical stocks, targeting companies with sustainable dividend capabilities and strong fundamentals [3]. - As of Q2 2025, the fund's main investments were concentrated in sectors such as in-hospital medical devices, equipment and consumables, in-hospital pharmaceuticals, and medical consumer products [3]. Risk Metrics - The fund's three-year Sharpe ratio was -0.0246, ranking 61 out of 105 comparable funds [10]. - The maximum drawdown over the past three years was 27.61%, with the largest single-quarter drawdown occurring in Q1 2022 at 21.42% [12]. Fund Composition - As of Q2 2025, the fund's total assets amounted to 50.68 million yuan [17]. - The top ten holdings included companies such as Aohua Endoscopy, Huatai Medical, and Heng Rui Medicine [19]. Portfolio Management - The fund has maintained a high average stock position of 92.95% over the past three years, compared to a comparable average of 86.95% [15].

2025 年 07 月 20 日 投资评级：看好（维持） 医药生物 行业走势图 -24% -12% 0% 12% 24% 36% 2024-07 2024-11 2025-03 医药生物 沪深300 数据来源：聚源 相关研究报告 《CXO 龙头中报业绩超预期，重点关 注板块后续行情 — 行 业 周 报 》 -2025.7.13 《艾伯维收购 Capstan，加码体内 CAR-T—行业周报》-2025.7.6 《多款减肥药亮相 2025 ADA，重点关 注 AMYR 与 ActRII 靶点—行业周报》 -2025.6.29 集采政策明确优化，继续推荐制药板块性机会 ——行业周报 | 余汝意（分析师） | 刘艺（联系人） | 聂媛媛（联系人） | | --- | --- | --- | | yuruyi@kysec.cn | liuyi1@kysec.cn | nieyuanyuan@kysec.cn | | 证书编号：S0790523070002 | 证书编号：S0790124070022 | 证书编号：S0790124050002 | 集采政策持续优化，仿创 pharma 有望估值重塑 集采政策优化基调明确， ...

Market Overview - The global endoscope market is experiencing steady growth, with projections indicating a market size exceeding $25.37 billion by 2024 and a compound annual growth rate (CAGR) of 5.3% until 2037, potentially reaching over $49.65 billion [1] - Different research firms provide varying estimates, with Global Market Insights forecasting a market value of $29 billion in 2024, growing to $56.9 billion by 2034, reflecting a CAGR of 6.9% [1] - The market is also expected to reach a sales scale of 283 billion yuan in 2024, with a forecasted growth to 387.64 billion yuan by 2030, indicating a CAGR of 7.4% [1] Market Segmentation - The flexible and rigid endoscope segments show strong growth potential, with the flexible endoscope market projected to grow from $8.98 billion in 2023 to $16.73 billion by 2033, at a CAGR of 6.42% [2] - The rigid endoscope market is expected to grow from $7.4 billion in 2023 to $14.7 billion by 2033, with a CAGR of 7.1% [2] - The single-use endoscope market is anticipated to grow rapidly, with a projected value of $4.57 billion in 2024, increasing to $5.43 billion in 2025, and reaching $21.86 billion by 2033, reflecting a CAGR of 19.01% [2] Key Market Drivers and Challenges - The rise in chronic diseases, particularly gastrointestinal diseases and cancers, is a significant driver for the endoscope market, with the WHO reporting 2.05 million deaths from cardiovascular diseases in 2021 [3] - Technological advancements in endoscope imaging, such as 4K and 8K imaging, narrow-band imaging, and AI integration, enhance diagnostic accuracy and treatment effectiveness [3] - The increasing prevalence of minimally invasive surgery (MIS) is also a key factor, as endoscopes are essential tools in these procedures [3] - Challenges include patient risks associated with endoscopic procedures, a shortage of trained professionals, and high costs of equipment, particularly in developing regions [4] Regional Market Analysis - North America leads the global endoscope market, valued at $19.2 billion in 2022, and is expected to account for about 40% of global revenue by 2037 [5] - The Asia-Pacific region is recognized as the fastest-growing market, driven by a large population, increasing economic strength, and rising healthcare awareness [6] - Europe holds a significant market share of approximately 28%, with strong markets in Germany and France due to advanced healthcare systems [7] Competitive Landscape - The endoscope market is highly concentrated, dominated by major multinational companies such as Olympus, Fujifilm, Karl Storz, and Stryker, which excel in technology development and product innovation [8] - Olympus leads the flexible endoscope market with a global market share of about 60% in 2024, while Karl Storz is a key player in the rigid endoscope segment [10][11] - The market is characterized by intense competition, with companies focusing on technological innovation, product performance, and pricing strategies [14] Technological Advancements - Recent advancements in imaging technology, including 4K and 3D imaging, are crucial for enhancing diagnostic capabilities [15] - The introduction of single-use endoscopes addresses issues of cross-infection and maintenance costs, with a significant increase in market presence since 2020 [17] - Capsule endoscopy technology allows for non-invasive examination of hard-to-reach areas, providing significant diagnostic advantages [20] Clinical Applications - Endoscopes are widely used across various medical fields, including gastroenterology, pulmonology, urology, gynecology, and general surgery, demonstrating their critical role in modern medicine [21] - The technology offers minimally invasive options, reducing recovery times and improving patient outcomes [22] - The penetration rate of endoscopic technology varies globally, with developed countries showing higher usage rates compared to developing regions [24][25] Future Outlook - The global endoscope market is expected to maintain robust growth, driven by aging populations, chronic disease burdens, and ongoing technological innovations [29] - The single-use endoscope market is projected to see explosive growth, particularly in infection control-sensitive areas [29] - AI integration in endoscopy is anticipated to enhance diagnostic accuracy and operational efficiency [30]

Core Insights - The report highlights the significant growth potential in the measurement and calibration industry, driven by new policies aimed at enhancing manufacturing capabilities in China [6][7][8] - The renewable energy sector, particularly in electric power equipment, is poised for growth due to supportive policies in the UK and increasing demand for energy storage solutions [13] - The pharmaceutical industry is recommended for investment, focusing on innovative drugs and their supply chains, with strong support from health insurance reforms [14] Industry and Company Analysis - **Measurement and Calibration Industry**: The first policy document from the Ministry of Industry and Information Technology emphasizes the need for precise measurement to drive innovation in manufacturing. This includes establishing a service network and digital transformation paths, with a focus on high-level calibration institutions and digital measurement software [6][7] - **Renewable Energy Sector**: The UK government has restarted subsidies for electric vehicles and charging infrastructure, indicating a robust market for energy storage systems. The report suggests focusing on companies involved in battery production and charging infrastructure, such as Ningde Times and Keda Technology [13] - **Pharmaceutical Industry**: The report continues to recommend innovative drug sectors, highlighting the recent adjustments in health insurance and commercial insurance that favor high-value innovative drugs. Companies like Kelun-Biotech and Innovent Biologics are noted for their strong potential in both domestic and international markets [14] - **Oil and Gas Sector**: China National Offshore Oil Corporation (CNOOC) has made significant advancements in oil and gas exploration, achieving record production levels in both domestic and international operations. The report anticipates continued growth in production capacity, particularly in the Stabroek block in Guyana [20][21][24]

Investment Rating - Industry investment rating: Stronger than the market (maintained) [1][23] Core Viewpoints - The demand for medical equipment bidding continues to be strong, with a significant recovery in procurement activities expected to improve company financial performance [3][5] - The overall market size for medical device bidding in China exceeded 80 billion yuan in the first half of 2025, showing a year-on-year growth of over 60% [3][11] - Major provinces driving the procurement include Liaoning, Hainan, Ningxia, Fujian, and Shanxi, with imaging equipment being the core focus of upgrades [3][5] Summary by Sections Market Trends - The procurement scale for medical devices has remained high since 2025, with June procurement figures showing significant year-on-year increases across various categories, such as ultrasound (1.391 billion yuan, +49%), CT (1.938 billion yuan, +59%), and MRI (1.531 billion yuan, +64%) [4][12][15] - The bidding recovery is evident, with monthly procurement figures for 2025 showing consistent growth, despite a slight slowdown in June [3][11] Company Performance - Leading companies are expected to benefit significantly from the recovery in equipment bidding, with firms like Mindray Medical projecting a noticeable recovery in overall performance starting from Q3 2025 [3][5][21] - In June 2025, the bidding amounts for major domestic companies were as follows: Mindray (623 million yuan, +15%), United Imaging (769 million yuan, +35%), and Kaili Medical (102 million yuan, +73%) [4][18] Investment Recommendations - The report suggests focusing on domestic leading enterprises that are enhancing their high-end and intelligent medical equipment layouts, such as Mindray Medical, United Imaging, Kaili Medical, and Aohua Endoscopy [5][21] - The continuous support for equipment updates from government policies is expected to positively impact the industry, with a projected increase in procurement activities [21]

Investment Rating - The industry investment rating is "Outperform the Market" [2][45] Core Insights - The total bidding amount for medical devices in June 2025 reached 12.618 billion yuan, representing a year-on-year growth of 30% and a total of 83.817 billion yuan for the first half of 2025, with an overall year-on-year increase of 64% [3][9][10] Summary by Sections Medical Device Bidding Overview - The medical device bidding amount in June 2025 was 12.618 billion yuan, showing a year-on-year increase of 30% and a quarter-on-quarter decrease of 6% [9] - The cumulative bidding amount for the first half of 2025 was 83.817 billion yuan, with a year-on-year growth of 64% [10] Domestic Brands - Mindray Medical's bidding amount in June 2025 was 623 million yuan, up 15% year-on-year, with a total of 4.258 billion yuan for the first half of 2025, reflecting a 64% increase [16][18] - United Imaging's June 2025 bidding amount was 769 million yuan, a 35% year-on-year increase, totaling 4.841 billion yuan for the first half of 2025, up 53% [13][14] - Aohua Endoscopy's June 2025 bidding amount was 27 million yuan, down 46% year-on-year, with a total of 235 million yuan for the first half of 2025, up 57% [19][20] - Kaili Medical's June 2025 bidding amount was 102 million yuan, a 73% year-on-year increase, totaling 642 million yuan for the first half of 2025, up 115% [22][23] - Shanwaishan's June 2025 bidding amount was 30 million yuan, a 222% year-on-year increase, totaling 186 million yuan for the first half of 2025, up 211% [25][26] - Wandong Medical's June 2025 bidding amount was 222 million yuan, a 416% year-on-year increase, totaling 728 million yuan for the first half of 2025, up 107% [28][29] Imported Brands - Philips' June 2025 bidding amount was 658 million yuan, down 4% year-on-year, with a total of 4.570 billion yuan for the first half of 2025, up 61% [31][32] - Siemens' June 2025 bidding amount was 978 million yuan, a 48% year-on-year increase, totaling 6.074 billion yuan for the first half of 2025, up 60% [34][35] - GE's June 2025 bidding amount was 1.447 billion yuan, a 49% year-on-year increase, totaling 6.736 billion yuan for the first half of 2025, up 56% [37][38]

Macro - In June 2025, China's export growth rate rose to 5.8%, driven by resilience in non-U.S. exports and "export grabbing" strategies towards the U.S. [4] - Looking ahead, the postponement of tariff deadlines to August 1 may sustain demand for Chinese exports, although global trade volumes are expected to decline if tariff policies are fully implemented [4] - Overall, China's exports may face slight pressure in the second half of the year, primarily due to a decline in global trade volumes rather than direct exports to the U.S. [4] Banking - In June 2025, loan issuance surged, with a slight year-on-year decrease in RMB loans for the first half of the year; corporate loans played a stabilizing role while retail credit showed seasonal growth [5] - New social financing reached 4.2 trillion yuan, with a growth rate of 8.9%, up 0.2 percentage points from the end of May [5] - M1 and M2 growth rates were revised upward, with the M2-M1 gap narrowing, indicating potential for continued positive performance in the banking sector [5] Materials - The price of polysilicon has increased for the first time in three months, while the price of praseodymium and neodymium oxide reached a 19-month high, indicating a positive outlook for the metal new materials sector [6] - Lithium prices have dropped to around 60,000 yuan per ton, with potential for accelerated capacity clearance; companies with cost advantages and resource expansion in the lithium sector are recommended for attention [6] - The extension of the cobalt export ban from the Democratic Republic of Congo by three months highlights ongoing strategic value in rare earth materials [6] Energy - Gansu Province has released a draft notice on establishing a capacity price mechanism for power generation, which is expected to benefit thermal power across the country, especially in regions with high wind and solar capacity [7] Company Updates - Chengzhi Shareholding (000990.SZ) anticipates a significant decline in net profit for H1 2025, projecting a net profit of 15 million to 22 million yuan, down 88.24% to 91.98% year-on-year [8] - Aohua Endoscopy (688212.SH) has received domestic certification for its new generation 4K ultra-high-definition endoscope system AQ-400 series, which is expected to drive growth upon market launch [9] - Yiling Pharmaceutical (002603.SZ) has received approval for its Qifang Nasal Tablets in Macau, marking a significant achievement in its R&D efforts, with expectations for improved performance throughout 2025 [10]

Core Viewpoint - The company is experiencing a decline in revenue due to industry performance and inventory adjustments, but is optimistic about future recovery and growth in overseas markets [4]. Group 1: Financial Performance - In Q1 2025, the company's revenue was 124 million, a year-on-year decrease of 26.92%, with a net profit attributable to shareholders of -28.79 million, indicating a shift from profit to loss [4]. - The decline in revenue is attributed to weak recovery in medical device procurement and proactive inventory adjustments by the company [4]. Group 2: Product Development and Market Position - The company launched the AQ-150 Series and AQ-120 Series endoscope systems in October 2024, enhancing its product lineup and market competitiveness [5]. - The AQ-150 Series features a 10.1-inch touchscreen and aims to simplify operations, while the AQ-120 Series is designed for versatility in various medical environments [5]. - The new AQ-400 series incorporates advanced hyperspectral technology, expected to enhance the company's competitive edge and drive sales growth in 2026 [5]. - Ongoing R&D efforts include the development of 3D flexible endoscopes, AI diagnostic technologies, and ERCP robots, aimed at improving safety, reliability, and convenience in future products [5]. Group 3: International Expansion - Since 2024, the company has been actively expanding its overseas marketing network, achieving product approvals and market promotion in multiple countries, which is expected to significantly boost brand influence and drive rapid growth in international business [4].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Views - The pharmaceutical sector underperformed the overall market this week, with the healthcare services sector leading the gains. The overall A-share market rose by 1.50%, while the biopharmaceutical sector increased by 1.82%, outperforming the market [1][33] - Merck announced a $10 billion acquisition of Verona Pharma to obtain the COPD drug Ohtuvayre, which is expected to be a significant product in the respiratory disease treatment market [2][10] - WuXi AppTec is projected to achieve a 102% increase in net profit for the first half of 2025, with revenues expected to reach 20.799 billion yuan, reflecting a growth of 20.64% [3] Summary by Sections Market Performance - The biopharmaceutical sector's price-to-earnings ratio (TTM) stands at 35.79x, which is at the 77.7 percentile of its historical valuation over the past five years [1][38] - The overall A-share market and various sub-sectors showed positive performance, with healthcare services up by 6.46% [1][33] Key Company Updates - Merck's acquisition of Verona Pharma will provide access to Ohtuvayre, a dual-target PDE3/4 inhibitor approved for COPD maintenance therapy, marking a significant advancement in treatment options [2][10] - Ohtuvayre's sales reached $71 million in Q1 2025, indicating strong market uptake and potential for expansion into other indications [22][24] Company Earnings Forecasts - WuXi AppTec's net profit for H1 2025 is expected to be 8.561 billion yuan, a 101.92% increase, driven by strong operational performance [3] - The report includes earnings forecasts for several companies, with WuXi AppTec and Mindray Medical both rated as "Outperform" [4][42] Investment Recommendations - Mindray Medical is highlighted as a leading domestic medical device company benefiting from new healthcare infrastructure and product upgrades [42] - WuXi AppTec is recognized for its comprehensive service capabilities in the new drug development outsourcing market [42] - Other recommended companies include New Industries, Huatai Medical, and Aibo Medical, each with strong market positions and growth potential [42][43][44]

Industry Research - The core viewpoint of the real estate market indicates a slight decline in new home transactions across 20 cities, with a total of 430,000 units sold, representing a decrease of 3.0%. Notably, Beijing saw a drop of 8% to 22,000 units, while Shanghai experienced a 4% increase to 54,000 units, and Shenzhen rose by 8% to 17,000 units. In the second-hand housing market, transactions increased by 13.7% to 422,000 units, with Beijing up 15% to 93,000 units, Shanghai up 21% to 138,000 units, and Shenzhen up 32% to 38,000 units [2]. Company Research - The report on Zijin Mining (601899.SH) forecasts a record high net profit attributable to shareholders of approximately 23.2 billion yuan for the first half of 2025, marking a year-on-year increase of about 54%. This growth is attributed to rising copper and gold prices. Projections for net profit in 2025, 2026, and 2027 are 47.06 billion, 54.65 billion, and 62.21 billion yuan, respectively, reflecting year-on-year growth rates of 47%, 16%, and 14%. The current stock price corresponds to a PE ratio of 11, 9, and 8 times for the respective years, maintaining an "overweight" rating [3]. - For China National Materials (600970.SH), the report highlights successful overseas expansion, with new contracts signed in the first half of 2025 showing significant growth. The company maintains a high dividend payout ratio, with a current dividend yield approaching 5%, making it competitive compared to banks. The forecast for net profit attributable to shareholders for 2025 to 2027 is 3.26 billion, 3.40 billion, and 3.52 billion yuan, respectively, sustaining a "buy" rating [4]. - The analysis of Aohua Endoscopy (688212.SH) anticipates that the AQ-400 series will meet clinical needs and drive revenue growth post-certification. The net profit forecasts for 2025 and 2026 have been adjusted down to 6.2 million and 9.5 million yuan, respectively, while a new estimate for 2027 is set at 13.6 million yuan. The current price corresponds to PE ratios of 101, 66, and 46 times, with the company maintaining a strong market position, thus retaining an "overweight" rating [5].